Browsing by Author "Al-Shamasi, Al Anood"
Now showing items 1-3 of 3
-
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
Al-Shamasi, Al-Anood; Elkaffash, Rozina; Mohamed, Meram; Rayan, Menatallah; Al-Khater, Dhabya; Gadeau, Alain-Pierre; Ahmed, Rashid; Hasan, Anwarul; Eldassouki, Hussein; Yalcin, Huseyin Cagatay; Abdul-Ghani, Muhammad; Mraiche, Fatima... more authors ... less authors ( MDPI , 2021 , Article)Abnormality in glucose homeostasis due to hyperglycemia or insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM). These metabolic abnormalities in T2DM lead to cellular dysfunction and the development of ... -
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
Abdulrahman, Nabeel; Ibrahim, Meram; Joseph, Jensa Mariam; Elkoubatry, Hanan Mahmoud; Al-Shamasi, Al Anood; Rayan, Menatallah; Gadeau, Alain Pierre; Ahmed, Rashid; Eldassouki, Hussein; Hasan, Anwarul; Mraiche, Fatima... more authors ... less authors ( Springer , 2022 , Article)Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been ... -
The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target?
Al-Shamasi, Al-Anood; Elsayed, Meram; Abdulrahman, Nabeel; Joseph, Jensa; Mraiche, Fatima ( Qatar University Press , 2020 , Poster)Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attention due to a recent clinical trial, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG ...